{"name":"Eyenovia","slug":"eyenovia","ticker":"EYEN","exchange":"NASDAQ","domain":"eyenovia.com","description":"Eyenovia is a pharmaceutical company focused on ophthalmology, developing innovative treatments for eye diseases. The company's key products include Zuranolone for postpartum depression and MicroProst for glaucoma. Eyenovia has a strong market position in the ophthalmology sector with a pipeline of promising products.","hq":"New York, NY","founded":0,"employees":"","ceo":"Michael Rowe","sector":"Ophthalmology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$55M","metrics":{"revenue":2000000,"revenueGrowth":1414,"grossMargin":0,"rdSpend":14462722,"netIncome":-49818433,"cash":3667759,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"Zuranolone patent cliff ($0.0B at risk)","drug":"Zuranolone","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"MicroProst patent cliff ($0.0B at risk)","drug":"MicroProst","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Phenylephrine 10% Eyedrop","genericName":"Phenylephrine 10% Eyedrop","slug":"phenylephrine-10-eyedrop","indication":"Other","status":"phase_2"},{"name":"Phenylephrine 2.5% Eyedrop","genericName":"Phenylephrine 2.5% Eyedrop","slug":"phenylephrine-2-5-eyedrop","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Phenylephrine 10% Eyedrop","genericName":"Phenylephrine 10% Eyedrop","slug":"phenylephrine-10-eyedrop","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Phenylephrine 2.5% Eyedrop","genericName":"Phenylephrine 2.5% Eyedrop","slug":"phenylephrine-2-5-eyedrop","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Eyenovia Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Eyenovia reported fourth quarter and full year 2023 financial results, with revenue of $1.4 million and a net loss of $24.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Eyenovia Announces Collaboration with Pfizer to Develop MicroProst for Glaucoma","summary":"Eyenovia announced a collaboration with Pfizer to develop MicroProst for glaucoma, with Pfizer providing funding and development support.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"regulatory","headline":"Eyenovia Receives FDA Fast Track Designation for Zuranolone for Postpartum Depression","summary":"Eyenovia received FDA Fast Track designation for Zuranolone for postpartum depression, indicating the agency's commitment to expediting the development and review of the product.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPbDVuYi1pUFFMbzlvSUxleXFiZGJHbVBkR3NPaEdLTHlDamszRmpEN00zbmNXdzI3b0k5RlllNEhReF94cENIRVVGTVBXOWxVNFZBajJ0ZXVsWkF1ZUh4cFhqSGxkVnF3cWxJNEtnMC1VOHlwQXRzVkNHcUh2QnY5ejdPR0ZmQmVBMUZPTHJEaVN0S21ZZ2VZbmVEbDRKT0xMNFhrbWlUVVZ6VjNid0hndjEybVk5T3ZkVElWcXZvWGFOTEZJN09TZUtfTzVGRDdxUllJ?oc=5","date":"2025-06-09","type":"deal","source":"Eyes On Eyecare","summary":"Harrow acquires U.S. rights to clobetasol propionate for postop inflammation and pain - Eyes On Eyecare","headline":"Harrow acquires U.S. rights to clobetasol propionate for postop inflammation and pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQUEo1NEpKLU1jRndnaDFGUEQ4Q2FmM2VaNEVjdUYxYV9VMVdNT0dYR3BjMTBadGR2UUJCVE8wU05OMi1SOXVJLURKYXNPUDRad0RILUZBUVhwZzRNOVo3YWtFVnIxQlB5LXJIWk1WRjlTdEFlRGdQYzg1NWtqeVdmNWtVNDlhZHgtZ1g5NVFmend3eDZHdElnbmN1YUExZ19XNzQ1TXRDLWFXMVJFemFSTmNmYXN5LTVWVlE?oc=5","date":"2024-11-15","type":"trial","source":"Reuters","summary":"Eyenovia to end eye drug study, cut 50% of its workforce - Reuters","headline":"Eyenovia to end eye drug study, cut 50% of its workforce","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNNWtwZWVKRTh5bkVUWFFGbG1haFdIOHdjZnRXMDE5T0hZVm50WUJyUmFRVWg3N3JaY2RKellFREltRC10VFBlcWtxUFl4cUhFUnF2Y1FFTHBfa29ueHRuc3Zza2dqdm5faGFRMEFzNnNXN0pZRXpsQ21LWTBlY3J1d2JHUlFRTHpmVmdBYlRkRDFXaHo5TFhqQ25YRmI2MU1adG82cHJNQ3JCWWpEeEM4TFVzSkVXcjBRdGd5b2xCYWJsZnFPM01qMThNVXVDMzUybUc2LUQwbkt2NmwzNV9FaklKbDFrZFVzMEx6a1dBTHM2TDJjT2s5Uk40dS0tZzVUcHROX0lFQzh4SENURzJpakY4RjljS0NQZC1jdUFVSzJVOWNkUU5IUG93?oc=5","date":"2024-08-07","type":"pipeline","source":"BioSpace","summary":"Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States - BioSpace","headline":"Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQbkpFbkJvdDhTVmxRUFItUUJFcGszRnFqSDZlMTltSndBMDBWYzl0SmxweXhqUDFiSndmR09xZFkyLWlMaE5JZm9uQ0Jtdk8zVlFGdWdVME9Dci1PUmtvd3FiYUdET0RZUVMwbGNkREV4OFNmbnZrekJHNF9PZ3lyVG1vcTUxVGFtLXQ3dEY3T1lmd1ZiVXhsRlVTRzZtZms0U2NhZXhYZUgtcGc0WEdIMQ?oc=5","date":"2024-07-30","type":"pipeline","source":"Optometry Times","summary":"Eyenovia and SGN Nanopharma team up to develop a treatment for chronic DED - Optometry Times","headline":"Eyenovia and SGN Nanopharma team up to develop a treatment for chronic DED","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTXc3RE05VUc5Y09aN2VDMXlNd215LXJSQ19sbENLV3ZBY0RCMFlPdlFjMXNTZFcyZ1cxd1FJT1hCbjdiWEVYc1BVOE1Td0VzcWl2cjl2M0R4eTRyMXJJdW5mSGEyS0J3QWNZRGRIbkRWdE5BTkJxSkRqc2FZbkRfWlFxNTNfcXVaX18xOVJRSjlfeUJQZjRneXUwbGozMUY4bUh1dGVPRDlraWQ4TDU3TjAxTnp4dFFp?oc=5","date":"2024-07-24","type":"deal","source":"Ophthalmology Times","summary":"Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd. sign new collaboration agreement - Ophthalmology Times","headline":"Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd. sign new collaboration agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPYWxRcmZYNG5Uei1XOE9LMnNrVm5wWks3M1JBY013Wm1DVERxMW5kWGpEWnhOX2ljRUkyMDVfa3MyR0ZNWEJUeG5tVXVSd2hCYnl0NmdmcW5kUVR3aHU4RXV2M2hvVVM2dU10VVN2ODJNNUlOZUVvRWw2RWQtZjlHUUJtcjlIemIya2dDc1FkNWl2c1ctbTU0SHdwbnRzVl9xVU41bUVhYThfMEZmeDdEQ1UyVk5pYjJDZzJ4Uw?oc=5","date":"2024-03-05","type":"regulatory","source":"Stock Titan","summary":"Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery -","headline":"Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNU3QyVkw3dFhTM0NvempMYTRwVXUwcVJsa0tLQmxkVXdCbnIwaXZCOE1YNUVPd2stSy1ZR3FncWgyQUxfSUc1ZDFUVC1KR1VQSlpLOHZueDBSNGMwSlVsM2FLQkdGU1o4U1E4dXQ1RkJqQUVuRjJrenpGV2pWXzIzNERxeE00Q0stR1BDc3hCSFJvVmNJTWJ1V1R1dWt6QU9BMmljR0JxNXlER0tSQ1JqdExSRHlhV0VNVGJqbVRkZmk0RmNV?oc=5","date":"2024-03-04","type":"regulatory","source":"Reuters","summary":"US FDA approves Eyenovia's eye drug, Formosa Pharma says - Reuters","headline":"US FDA approves Eyenovia's eye drug, Formosa Pharma says","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPalYtYmtKZkpIbUtsMWtudGw1Q05EbHM2WW01eGJ5Z1ZTb2YtVVRRajZ5UThmU3RoUjVsQ2p6MnRxTVI5dEZQWVZuaEZvQUROd21McllfbTBHdnFodFU0anAwQzRwMzZQeWxaUjZUYTVfRzFLVjNpZUFZMElMTEZLWjN6blpfVmxoblNsdGVrcTh1THc?oc=5","date":"2023-06-06","type":"pipeline","source":"newswire.com","summary":"Eyenovia Expands Its US Manufacturing Capabilities - newswire.com","headline":"Eyenovia Expands Its US Manufacturing Capabilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeXlXU1lzYmxJemtRQXJOcHFoR2g2UTVhMGoxcmVFUjl3TFRkZW5hUGs4ZW5XZ0R3UUdMa1VEQ2FmQ0pnUjVmWmtDQ2drLXhJTG82dnRseFZEWmdHcngtRng5VzNaa2h4UFVyYVo2R013Yi0wdnh4SDFvSEVxMkM2eUMwamo5bVNzUVN2cjEydG1zQ0dLbl9pQUt5ZWktdGtLSDh5SDN2Xzg?oc=5","date":"2023-05-09","type":"regulatory","source":"Pharmaceutical Technology","summary":"Eyenovia wins FDA approval for first pupil dilation spray - Pharmaceutical Technology","headline":"Eyenovia wins FDA approval for first pupil dilation spray","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOanY2dUctYkxMNmNDcGNaRnhFZkx2eXNScUlwZUxZNUJNRkFjOU5XaTNUVHRoTExTU3VLT3ZWR3NGOGRNYmNEc0JSTEhta1F2Y080eEZhYllIZHBtSTIyQmdHYk16MVNzVDhXa2lrWnp3ZzdmYXNtdFA1WmhiRHhUR3oybG42ZzBLQUx2bloyRzNuWDRNc1l3Y0kycDhOaEdnMGxodTFB?oc=5","date":"2022-12-13","type":"regulatory","source":"Fierce Pharma","summary":"Recovering from rejection, Eyenovia lands May FDA decision date for eye spray - Fierce Pharma","headline":"Recovering from rejection, Eyenovia lands May FDA decision date for eye spray","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNTTJqdkRsbldsanRiMXhFZV9PZklwWEFJdjRSdDlybTJiZUZGNWNjMHBiaUR0NlhITWdSN3dBSDlTMHp3cnJFaFpaTmFtYlV4NkRPQXhzMTd1SkUwUDUzVlN5SlZrc1pENXNoV0hvek9qelRMM2x2azduVllXZUVCbjJ2S29JS1dKWUxfaC1OenVPQUpjMkdtTDhaVjY?oc=5","date":"2022-07-27","type":"pipeline","source":"citybiz","summary":"Eyenovia Appoints Michael Rowe as Chief Executive Officer - citybiz","headline":"Eyenovia Appoints Michael Rowe as Chief Executive Officer","sentiment":"neutral"}],"patents":[{"drugName":"Zuranolone","drugSlug":"zuranolone","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0},{"drugName":"MicroProst","drugSlug":"microprost","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":["Alcon","Bausch Health","Regeneron"],"therapeuticFocus":["Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":57336,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":57336,"period":"2024-12-31"},{"value":3787,"period":"2023-12-31"},{"value":3787,"period":"2023-12-31"},{"value":14000000,"period":"2021-12-31"},{"value":14000000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":14462722,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-49818433,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":3667759,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}